To the Editor:
Maes and colleagues (1) present data from lung tissue that showed that mRNA expression for ACE2 (angiotensin-converting enzyme 2) was significantly greater in 38 patients with moderate chronic obstructive pulmonary disease (COPD) compared with 61 healthy control subjects but not compared with a group of 7 patients with asthma or asthma–COPD overlap syndrome. Furthermore, values for ACE2 expression in a heterogeneous group of 23 patients with obstructive airway disease (OAD) comprising COPD, asthma–COPD overlap syndrome, or asthma not receiving inhaled corticosteroids (ICS) were significantly higher than values in 56 control subjects but not values in 25 patients with OAD receiving ICS.
The problem with interpreting these results in a heterogeneous group of patients with OAD is that ACE2 is upregulated in smokers and in those with COPD but is downregulated in those with asthma and those with atopy (2, 3). Furthermore, assaying ACE2 mRNA only tells one-half of the story with regard to entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into lung tissue, as asthma and atopy are both associated with upregulation of TMPRSS2 (transmembrane protease serine 2) in airway epithelial cells (3). In this regard, in induced sputum cells from asthma patients, ICS have been shown to exhibit suppressive effects ex vivo on both ACE2 and TMPRSS2 expression (4).
Maes and colleagues (1) fail to point out the inhibitory in vitro effects of ICS on local and systemic production of IL-6 (5, 6), this being the strongest predictor for impending respiratory failure in severe coronavirus disease (COVID-19) (7). Finally, a more specific suppressive effect from ICS on SARS-CoV-2 replication has been described with ciclesonide and mometasone furoate but not with budesonide, beclomethasone, or fluticasone (8).
We believe that, taken together, these observations reinforce the need for patients with eosinophilic asthma and COPD to continue receiving their controller therapy containing ICS, as that will provide optimal disease control and perhaps also confer protection against viral triggers, perhaps including SARS-CoV-2.
Supplementary Material
Footnotes
Originally Published in Press as DOI: 10.1164/rccm.202005-2000LE on July 15, 2020
Author disclosures are available with the text of this letter at www.atsjournals.org.
References
- 1. Maes T, Bracke K, Brusselle GG. COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids? [editorial] Am J Respir Crit Care Med. 2020;202:8–10. doi: 10.1164/rccm.202005-1651ED. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146:203–206, e3. doi: 10.1016/j.jaci.2020.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020;146:80–88, e8. doi: 10.1016/j.jaci.2020.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19–related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202:83–90. doi: 10.1164/rccm.202003-0821OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Suda K, Tsuruta M, Eom J, Or C, Mui T, Jaw JE, et al. Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol. Am J Respir Cell Mol Biol. 2011;45:510–516. doi: 10.1165/rcmb.2010-0169OC. [DOI] [PubMed] [Google Scholar]
- 6. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58:155–168. doi: 10.1016/j.resinv.2019.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146:128–136, e4. doi: 10.1016/j.jaci.2020.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 [preprint] bioRxiv. 2020. [accessed 2020 Jul 5]. Available from: https://www.biorxiv.org/content/10.1101/2020.03.11.987016v1. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.